FIRST HALF 2023 RESULTS CONFIRM STRONG MOMENTUM OF THE GROUP: REVENUE +17.0%, EBITDA +21.3%, ADJUSTED NET INCOME +27.9%. RECENT TRANSACTION WITH GSK FURTHER STRENGTHENS SPC UROLOGY FRANCHISE
This website contains information about products that may not be available in all countries or may be available under different trademarks, for different indications, or in different doses. If you are a US resident please click the button below.
